- Two unnamed sources told Reuters Anthropic set up a wet lab in the Bay Area.
- Company’s stated goal: unlock treatments for rare diseases and expand life‑sciences work beyond in‑silico evaluation.
- Sources say Anthropic is targeting lab automation with Claude directing robotic systems.
- Reportedly Anthropic intends not to run clinical trials to avoid direct competition with established drugmakers.
- A company life‑sciences lead commented on focusing on discovery and preclinical work (as quoted in Reuters).
- Reuters characterizes the disclosure as ‘quiet’ — not previously public from Anthropic’s channels.
- Physical biology work by AI companies attracts regulatory and biosecurity scrutiny.
- If Claude is used to direct lab automation, oversight, validation, and supply‑chain controls will be relevant to regulators and partners.
- Reuters reporting is sourced to two people familiar with the matter; the story is not a company blog post or press release.
Useful?